Analysts picked the top 4 blockbuster contenders in the mix — and #1 is a $3.8B coin toss
Every year, the analysts at Clarivate sort through the numbers to see how many have a legitimate shot at breaking into the championship ring of $1 billion-plus blockbusters.
Now, for the 8th straight year, they have a short list for which drugs bidding for — or recently achieving — an FDA approval. And some of the picks may surprise you.
At the top, way out in front on peak potential sales with a potential $3.8 billion annual bonanza, sits aducanumab, perhaps the most controversial therapy that’s made it through an expert panel review — after Sarepta’s eteplirsen.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 150,500+ biopharma pros reading Endpoints daily — and it's free.